JLC062 / Jecho Biopharma - LARVOL DELTA

Rational design of a B7-H3/PD-L1 bsADC combining checkpoint blockade with targeted cytotoxicity for improved antitumor efficacy (AACR 2026) - "It exhibited robust PD-1/PD-L1 blocking activity and induced IL-2 and IFN-γ secretion levels comparable to the clinical benchmark avelumab in a mixed lymphocyte reaction assay. In a syngeneic mouse model, JLC062 demonstrated significantly greater antitumor efficacy than either parental monotherapy, anti-PD-L1 antibody or anti-B7-H3 ADC, with no observed body weight loss. These findings highlight JLC062 as a promising therapeutic modality that integrates immune checkpoint inhibition with targeted cytotoxic delivery to yield deep and durable antitumor responses."

ADC • Checkpoint block • Checkpoint inhibition • Clinical • IO biomarker • Oncology • Solid Tumor • CD276 • IFNG • IL2 • PD-L1